Implementation of Pharmacogenetic Testing in Hospital Wards
FAGLIS
1 other identifier
interventional
46
1 country
1
Brief Summary
The purpose of this study is to investigate whether it is feasible to implement pharmacogenetic testing as part of medication review while the patient is admitted to hospital.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Oct 2020
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 25, 2020
CompletedFirst Posted
Study publicly available on registry
October 5, 2020
CompletedStudy Start
First participant enrolled
October 5, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2021
CompletedMarch 9, 2023
March 1, 2023
1.1 years
September 25, 2020
March 8, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Number of patients with results from pharmacogenetic testing included in medication review
Number of patients
from admission to discharge, an average of 1 week
Secondary Outcomes (2)
Acceptance of recommendations
after medication review and before discharge, an average of 3 days
Documentation of information from pharmacogenetic testing
after medication review and before discharge, an average of 3 days
Study Arms (1)
Pharmacogenetic test
EXPERIMENTALMedication review including results from pharmacogenetic testing
Interventions
systematic and interdisciplinary method aiming to increase quality of medication treatment
Eligibility Criteria
You may qualify if:
- at least 2 long-term conditions
- at least 5 regular drugs of which at least one relevant for pharmacogenetic testing
- at least 2 years life expectancy
- able to communicate in Norwegian
- able to give informed consent
- summary care record
You may not qualify if:
- moderate to severe dementia
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Hospital Pharmacy Enterprise, South Eastern Norwaylead
- University Hospital, Akershuscollaborator
- Diakonhjemmet Hospitalcollaborator
- University of Oslo School of Pharmacycollaborator
Study Sites (1)
Akershus University Hospital
Lørenskog, Nordbyhagen, 1478, Norway
Related Publications (1)
Hjemas BJ, Bovre K, Bjerknes K, Mathiesen L, Mellingsaeter MCR, Molden E. Implementation of pharmacogenetic testing in medication reviews in a hospital setting. Br J Clin Pharmacol. 2023 Oct;89(10):3116-3125. doi: 10.1111/bcp.15815. Epub 2023 Jun 22.
PMID: 37277227DERIVED
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Kathrin Bjerknes, Ph.D
Hospital Pharmacy Enterprise, South Eastern Norway
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 25, 2020
First Posted
October 5, 2020
Study Start
October 5, 2020
Primary Completion
November 1, 2021
Study Completion
November 1, 2021
Last Updated
March 9, 2023
Record last verified: 2023-03
Data Sharing
- IPD Sharing
- Will not share